PATENT CLAIM ANALYSIS

Application Number: 15910788
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-09
Patent Classification: ["424", "181100"]

Abstract:
The present disclosure provides antibody drug conjugates that bind human cMET, their methods of making, and their uses to treat patients having cancer.

Claim (Index 138):
A method of treating a non-small cell lung cancer (\u201cNSCLC\u201d) that overexpresses cMet, comprising administering to a human subject having said NSCLC an anti-cMet antibody drug conjugate (\u201cADC\u201d), wherein the drug conjugate is monomethyl auristatin E (\u201cMMAE\u201d), and the ADC has the following structure: wherein Ab is an anti-cMet antibody comprising a VH chain comprising three CDRs, namely VH CDR #1 (SEQ ID NO:112), VH CDR #2 (SEQ ID NO: 113) and VH CDR #3 (SEQ ID NO: 114); a VL chain comprising three CDRs, namely VL CDR #1 (SEQ ID NO: 115), VL CDR #2 (SEQ ID NO: 116) and VL CDR #3 (SEQ ID NO: 117); and a modified hinge region of SEQ ID NO: 170, n has a value ranging from 2 to 8, and, wherein said NSCLC has a biopsy IHC score of 2+ to 3+.

Metadata:
- Claim Count in Document: 47.0
- Percentile: 90.0
- Lexical Diversity: 1.08333
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15363786', '15363715', '15819153', '14928738', '15747620']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7357152935165348
- 35 USC 102 Novelty (BERT): 0.5394756454755557
- Combined Prediction Score: 0.7160913287124369
- Mean Citation Score: 322.025672
- Max Citation Score: 361.72943
- Similarity Product: 249.9442286726028

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test